Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03002259
Registration number
NCT03002259
Ethics application status
Date submitted
21/12/2016
Date registered
23/12/2016
Date last updated
11/01/2023
Titles & IDs
Public title
Dexamethasone for Cardiac Surgery-II Trial
Query!
Scientific title
Evaluation of Dexamethasone in Cardiac Surgery Using a Novel Trial Design
Query!
Secondary ID [1]
0
0
69
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
DECS-II
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Inflammatory Response
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Dexamethasone
No Intervention: Control - No placebo required
Active Comparator: Dexamethasone - Dexamethasone, 1 mg/kg (maximal dose 100 mg), single dose administration before cardiopulmonary bypass
Treatment: Drugs: Dexamethasone
Dexamethasone administered as a single IV injection after induction of anaesthesia, but before initiation of CPB. Prepare as a 20 mg/mL dexamethasone solution, made up with 0.9% saline to 10 ml.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
days at home up to 30 days after surgery
Query!
Assessment method [1]
0
0
Home is defined as a person's usual abode or that of a close relative, excluding any nursing facility (rehabilitation center or nursing home).
Query!
Timepoint [1]
0
0
30 days from Start of Surgery
Query!
Secondary outcome [1]
0
0
respiratory failure
Query!
Assessment method [1]
0
0
Uninterrupted postoperative mechanical ventilation for more than 48 hours from admission to ICU
Query!
Timepoint [1]
0
0
30 days from Start of Surgery
Query!
Secondary outcome [2]
0
0
Infection
Query!
Assessment method [2]
0
0
Surgical site infection, pneumonia, or documented positive microbial culture from any site (including blood).
Query!
Timepoint [2]
0
0
30 days from Start of Surgery
Query!
Secondary outcome [3]
0
0
Myocardial Infarction
Query!
Assessment method [3]
0
0
Postoperative myocardial infarction will be defined according to the third universal definition
Query!
Timepoint [3]
0
0
30 days from Start of Surgery
Query!
Secondary outcome [4]
0
0
Stroke
Query!
Assessment method [4]
0
0
A new neurological deficit lasting more than 24 hours or leading to earlier death, and confirmed by medical imaging.
Query!
Timepoint [4]
0
0
30 days from Start of Surgery
Query!
Secondary outcome [5]
0
0
Peak blood glucose
Query!
Assessment method [5]
0
0
The highest blood glucose measured in this same period
Query!
Timepoint [5]
0
0
30 days from Start of Surgery
Query!
Secondary outcome [6]
0
0
Length of stay
Query!
Assessment method [6]
0
0
Time from postoperative ICU admission to ICU discharge (hours) and hospital discharge (days).
Query!
Timepoint [6]
0
0
30 days from Start of Surgery
Query!
Secondary outcome [7]
0
0
Quick SOFA score
Query!
Assessment method [7]
0
0
Tachypnoea, altered mentation and/or hypotension
Query!
Timepoint [7]
0
0
Each evening on days 1-3 after surgery
Query!
Eligibility
Key inclusion criteria
1. Males and females, age 18 to 75 years undergoing elective cardiac surgery with
cardiopulmonary bypass
2. EuroScore-II estimated risk of 1.5% or higher
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Poor language (English or Dutch) comprehension
2. Type I diabetes
3. Endocarditis or other evidence of sepsis
4. Preoperative steroid therapy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
31/01/2023
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1956
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Alfred Health - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3004 - Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Bayside Health
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
UMC Utrecht
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Background. Numerous studies have investigated high-dose corticosteroids in cardiac surgery,
but with mixed results leading to ongoing variations in practice around the world. The
Dexamethasone for Cardiac Surgery-II Trial (DECS-II) is a study comparing high-dose
dexamethasone with placebo in patients undergoing cardiac surgery.
Methods. We discuss the rationale for conducting DECS-II, a 2800-patient, pragmatic,
multicenter, assessor-blinded, randomized trial in cardiac surgery, and the features of the
DECS-II study design (objectives, end points, target population, balanced clusters based on
practice preference with post-randomization consent, treatments, patient follow-up and
analysis).
Conclusions. The DECS-II Trial will use a novel, efficient trial design to evaluate whether
high-dose dexamethasone has a patient-centered benefit of enhancing recovery and increasing
the number of days at home after cardiac surgery.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03002259
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Paul S Myles, MBBS, MD
Query!
Address
0
0
Alfred Hospital, Monash University
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03002259
Download to PDF